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 Introduction 
 Th e metabolic syndrome represents a combination of physical and 
biochemical fi ndings including central adiposity, hypertension, 
dyslipidemia, infl ammation, and impaired glucose tolerance that 
predispose aff ected individuals to atherosclerotic cardiovascular 
disease (ASCVD) and type 2 diabetes mellitus (T2DM). 1–6 Insulin 
resistance is the key metabolic feature of the metabolic syndrome, 3–6 
and in addition to ASCVD and T2DM is considered to play a 
major role in the pathogenesis of hepatic steatosis, polycystic 
ovary disease, and certain forms of cancer. 7 One in three to four 
adults in the United States  currently has metabolic syndrome, 
and over 90% of individuals with diabetes are insulin resistant; 
thus, insulin resistance and its related metabolic disturbances are 
a signifi cant cause of morbidity and mortality. 
 The incidence and prevalence of insulin resistance and 
metabolic syndrome in the United States has increased 
dramatically over the past several years, 5,6 , 8 and we and others 
have proposed that this increase may in part be attributable to 
increased consumption of fructose derived from dietary sugars, 
principally sucrose and high-fructose corn syrup (HFCS). 9–11 
Fructose intake in countries adopting a Western diet has increased 
markedly over the past three decades. In the United States alone, 
yearly per capita caloric sweetener consumption is estimated 
to have risen approximately 20% since 1970, 12 coinciding with 
the obesity epidemic, and recent self-reported food intake data 
from the National Health and Nutrition Examination Survey 
(NHANES) suggest that approximately 15% of the US population 
consumes ≥25% of energy from added sugars. 13 Sugar-sweetened 
beverages (SSBs) in particular are the largest source of added 
sugars in the Western diet, accounting for more than 10% of 
energy intake; 14 their consumption increased by approximately 
135% between 1977 and 2001, 15 contributing to an increase in the 
consumption of all caloric sweeteners of approximately 83 kcal/
person/day. 16 Importantly, increased fructose consumption from 
sucrose (50% fructose) or HFCS (42–55% fructose), particularly 
in the form of SSBs, has also been implicated in promoting weight 
gain, visceral adiposity, dyslipidemia, and insulin resistance/
glucose intolerance 9–11 , 17–19 —all components of the metabolic 
syndrome. 
 A major limitation to the study of the metabolic syndrome 
and T2DM in humans, and particularly the pathogenesis of these 
disorders and their related metabolic abnormalities, is the lack of 
relevant animal models with which to rigorously investigate the 
progression and biological mechanisms of the disease processes. 
Numerous animal studies, mostly conducted in rodents, have 
shown that diets high in fructose produce metabolic perturbations 
associated with the metabolic syndrome and T2DM. 10 , 20 However, 
important metabolic differences exist between rodents and 
primates, particularly with respect to lipoprotein metabolism, 
the major site of lipogenesis (liver vs. adipose), and the physiology 
of thermogenesis. Th erefore, the results of metabolic studies 
performed in primates are substantively more applicable to 
human physiology and medicine than those from rodent 
studies, underscoring the importance of developing standardized 
nonhuman primate models of insulin resistance for the study of 
metabolic syndrome and T2DM. 
 Many characteristics of the rhesus monkey ( Macaca mulatta ) 
make the species ideal for this purpose. Th ey are relatively large 
animals, are easy to maintain in captivity, and have a lifespan 
of approximately 25 years, making them suitable for long-
term dietary and disease prevention and intervention studies. 
Furthermore, compared with rodents, they exhibit greater 
similarity to human physiology and susceptibility to metabolic 
diseases, 21 and have been shown to develop insulin resistance, 
dyslipidemia, hypertension, and T2DM with adult-onset 
obesity. 22,23 In addition, the rhesus monkey genome has been 
sequenced, 21 , 24 enabling comparative genetic studies with humans. 
Th e human and rhesus monkey genomes are approximately 93% 
similar, and the two species are believed to have shared a common 
ancestor approximately 25 million years ago. 21 In contrast, and 
again underscoring the importance of nonhuman primates in 
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biomedical research, rodents are believed to have separated 
from humans greater than 70 million years ago. 25,26 Although the 
chimpanzee and human genomes, which diverged approximately 
6 million year ago, are approximately 98% identical, most of the 
diff erences in both the rhesus monkey and chimpanzee genomes 
are on the level of gene rearrangements rather than single gene 
mutations, preserving the closeness of their phenotype with 
humans and validating the use of the rhesus monkey as a primate 
model in which to study human diseases. 
 Th rough our collaborations with the California National 
Primate Research Center (CNPRC), our laboratory has 
previously used rhesus monkeys to successfully study complex 
human metabolic traits. 27–31 Importantly, the results derived 
from those studies have paralleled the results of later studies 
performed in humans, 32,33 reinforcing the utility of the rhesus 
monkey as an animal model for investigating the physiology 
of human metabolism and the pathophysiology of metabolic 
derangements. Moreover, studies performed in rhesus monkeys 
have been instrumental in enhancing our understanding of 
the autonomic regulation of glucagon secretion in response 
to insulin-induced hypoglycemia, 34 the autonomic response 
to meal-induced insulin secretion, 29 the pharmacokinetics 
of leptin, 35 the autonomic eff ects of leptin, 36 comparing the 
endocrine and metabolic eff ects of glucose and fructose, 30,31 
and investigating new therapeutic strategies for the treatment 
of insulin resistance. 37 
 We recently reported that consumption of fructose-
sweetened beverages at 25% of daily energy requirements in older, 
overweight/obese men and women increases visceral adipose 
deposition and  de novo lipogenesis, produces dyslipidemia, 
and decreases glucose tolerance/insulin sensitivity. 19 Since the 
commonly consumed dietary sugars, sucrose and HFCS, consist 
of 50% and 42–55% fructose, respectively, these results provide 
a potential mechanistic link between sugar consumption and 
metabolic disease. Accordingly, we have been conducting 
studies evaluating the long-term metabolic eff ects of fructose 
consumption in rhesus monkeys in parallel with our clinical 
research in humans. Specifi cally, we hypothesized that rhesus 
monkeys consuming fructose-sweetened beverages for 1 
year would develop components of the metabolic syndrome, 
including insulin resistance and dyslipidemia. Furthermore, 
given the long-term time course of the intervention, we 
hypothesized that a subset of the animals might develop overt 
T2DM. 
 Materials and Methods 
 Animals 
 Th e rhesus monkeys used for this study were provided by the 
California National Primate Research Center (CNPRC) and 
maintained at the CNPRC at the University of California, 
Davis. Protocols for all the animal studies were approved by the 
University of California, Davis Institutional Animal Care and Use 
Committee and conducted in accordance with the Department 
of Agriculture Animal Welfare Act and the National Institutes 
of Health’s  Guide for the Care and Use of Laboratory Animals . A 
total of 29 adult male rhesus monkeys, age 12–20 years (body 
weight 16.3 ± 0.4 kg) were studied. At baseline, all monkeys had 
fasting plasma glucose concentrations <100 mg/dL, fasting insulin 
concentrations <100 μU/mL, fasting plasma TG concentrations 
<100 mg/dL, and a percent body fat >20%. 
 Diet and energy intake measurements 
 A commercial monkey chow diet (Lab Diets 5047, Advance Protocol 
Old World Primate; PMI, St. Louis, MO, USA) was provided  ad 
libitum to all the monkeys. Th is is a grain-based standard primate 
diet that provides 30% energy as protein, 11% energy as fat, and 59% 
energy as carbohydrate. In addition, all monkeys were provided 500 
mL/day of a fruit-fl avored (Kool-Aid, Kraft  Foods, Northfi eld, IL, 
USA) 15% fructose-sweetened beverage (75 g of fructose). Beverage 
intake was recorded daily and food intake was recorded for 1 week 
at baseline, and then for 1-week periods at 3-month intervals during 
the 12-month-study period. 
 Energy expenditure 
 Metabolic rate measurements were performed at the CNPRC 
Exposure Facility. The system consisted of two airtight 
32h × 27d × 24w chambers. Positive airfl ow into the chambers 
was regulated with a mass fl ow controller and was set at a rate of 
21 mL/min. A reference line and sample lines to the two chambers 
were connected to a multiplexer to allow for serial sampling of 
the three lines. A fl ow controller with a negative fl ow rate of 
100 mL/min pulled the sample through the multiplexer, then 
through a CO 2 analyzer (AEI Technologies, Pittsburgh, PA, 
USA), drierite column, and O 2 analyzer (AEI Technologies). 
Th e multiplexer switched between the three lines at 10-minute 
intervals, thereby allowing a measurement to be taken from each 
chamber at 30-minute intervals. Each 10-minute interval consisted 
of three CO 2 and O 2 readings which were averaged and recorded 
using a data acquisition system and LabView soft ware (National 
Instruments, Austin, TX, USA). Energy expenditure was then 
calculated using the Weir equation. 38 Monkeys were put into the 
chambers between 7 and 9 AM along with their fructose beverage 
plus  ad libitum food and water, left  in the chambers overnight 
and returned to their home cages the following morning. Th ey 
rested for a day and then were put back in the metabolic chambers 
for another measurement. Th is was repeated for a total of four 
metabolic rate measurements for each animal. Th e mean of the 
four measurements was calculated for the fi nal data set. Th e AUC 
was calculated using the trapezoidal method. 
 Body weight and body adiposity 
 Animal body weight was determined monthly. At baseline, 
6 months, and 12 months, percent and total body fat were 
determined by dual-energy x-ray absorptiometry (DEXA), a 
sensitive technique for measuring body fat, 39 which has been 
previously validated for the determination of body composition 
in monkeys. 40 
 Intravenous glucose tolerance tests (IVGTTs) 
 At baseline, 6 months, and then 12 months, IVGTTs were 
performed. For each test, the animals were anesthetized with 
ketamine (10 mg/kg IM) and an intravenous (IV) catheter was 
inserted in each arm vein. Supplemental ketamine was given as 
an IV infusion at a rate of 0.25–1.0 mg/kg/min, and the infusion 
rate adjusted to maintain a stable plane of anesthesia as assessed 
by monitoring blood pressure, heart rate, respiratory rate, and 
muscle tone. Three baseline samples (3 mL) were collected 
from one catheter at –10, –5, and 0 minutes. Subsequently, 
600 mg/kg of 50% dextrose was administered via the contralateral 
catheter. Additional 3 mL blood samples were collected at 1, 3, 
5, 10, 15, 20, 30, 40, and 60 minutes. Th e AUC for glucose and 
insulin during the IVGTTs was calculated using the trapezoidal 
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method, and glucose tolerance was estimated by the area 
above baseline under the glucose curve from 0 to 60 minutes. 
An index of insulin sensitivity was calculated by dividing the 
slope of the glucose disappearance between 5 and 20 minutes 
(when it is quite linear) by the area under the insulin curve as 
described previously. 37 We have also demonstrated that measuring 
deuterated glucose disposal (a technique that has been validated 
with hyperinsulinemic euglycemic clamps in humans), we obtain 
results that are highly correlated ( r 2 = 0.84,  p < 0.001) with the 
insulin sensitivity index calculated with the slope of the glucose 
disappearance. 
 Glucose, insulin, and HOMA-IR 
 Plasma insulin concentrations were measured using an RIA 
(Millipore, St. Charles, MO, USA), and plasma glucose levels 
were measured with a YSI Glucose Analyzer (Yellow Springs, OH, 
USA). Th e HOMA-IR was calculated using the following equation: 
([fasting glucose (mmol/L) × fasting insulin (μU/mL)]/22.5). 41 
 Lipid and lipoproteins 
 Total cholesterol, HDL-C, LDL-C, TG, apoA1, apoB, and apoC3 
concentrations were determined using a Polychem Chemistry 
Analyzer (PolyMedCo, Inc. Cortlandt Manor, NY, USA). Oxidized 
LDL-C levels were measured with a commercially available ELISA 
(Mercodia, Inc., Winston Salem, NC, USA). 
 Adipocyte hormones 
 Plasma total adiponectin was measured using an RIA (Millipore), 
and HMW adiponectin oligomer concentrations were measured 
by ELISA (Alpco, Salem, NH, USA). Plasma leptin concentrations 
were measured by RIA (Linco Research Inc., St. Charles, MO, 
USA). 
 Proinfl ammatory markers 
 Plasma CRP levels were measured using a Polychem Chemistry 
Analyzer (PolyMedCo, Inc.), and plasma MCP-1 and PAI-
1 concentrations were measured by ELISA (R&D Systems, 
Minneapolis, MN, USA). 
 Statistical analysis 
 Values are presented as the mean ± SEM. In the monkeys that 
developed metabolic syndrome but not T2DM ( n = 25), a linear 
mixed model was used to assess the longitudinal trend of the 
data. Th is model incorporates random intercepts for each of the 
monkeys to account for repeated measures, and time was regarded 
as a multilevel categorical variable. Prior to the analyses, the 
distributions of each outcome variable were assessed for normality; 
for those outcome variables with skewed distributions, log 
transformations were applied to meet the normality assumptions of 
the linear mixed model. For all outcome variables, the magnitudes 
of change between baseline and each follow-up measurement was 
calculated, along with corresponding 95% confi dence intervals 
and  p values. For each outcome requiring a transformation, the 
estimated diff erences between time points were back transformed 
to represent the geometric means with corresponding 95% 
confi dence intervals and  p values. Percent diff erences (%) from 
baseline to 6 and 12 months for each outcome variable were 
calculated using arithmetic or geometric means from the linear 
mixed models, with  p values corresponding to the diff erence in 
model-based means at each time point from baseline. All trend 
analyses were performed using the statistical soft ware R 2.10.0 
( http://www.r-project.org ). In addition, the Pearson’s correlation 
coeffi  cient ( r ) between the HOMA-IR and ISI values at each time 
point was calculated using the Stata data analysis and statistical 
soft ware package (StataCorp LP, College Station, TX, USA). Given 
that the number of monkeys that developed diabetes throughout 
the course of the study was small ( n = 4), only descriptive statistics 
are presented for the outcome variables in these animals, and the 
percent diff erences (%) from baseline to 6 and 12 months for 
each outcome variable were calculated using raw means. 
 Results 
 Study cohort. During the course of the 12-month study, every 
monkey ( n = 29) developed components of the metabolic 
syndrome (principally increased body adiposity, insulin resistance, 
and dyslipidemia); four monkeys (~15% of the study cohort) 
developed frank T2DM (defi ned by a fasting blood glucose 
concentration ≥126 mg/dL). 
 Body weight, body fat, energy intake, and energy expenditure. In 
the monkeys that did not develop diabetes, body weight increased 
from 16.4 ± 0.4 kg at baseline to 17.9 ± 0.6 kg at 12 months 
(+9%,  p  0.001,  Figure 1A ). In addition, fat mass increased by 
+29% at 6 months, ( p < 0.001) and +34% at 12 months ( p  
0.001) ( Figure 1B ), as did percent body fat (+16% at 6 months,  p 
 0.001; +15% at 12 months,  p  0.001). Average daily energy 
intake increased by 26 kcal/day during the study period ( Figure 
1C ), whereas average daily energy expenditure decreased (13% 
at 6 months,  p  0.001; 10% at 12 months,  p  0.01) ( Figure 
1D ). In particular, the animals showed a progressive decrease in 
fat oxidation throughout the study period (23.0 ± 2.4 mg/min/kg 
× 21 hr at baseline vs. 22.5 ± 1.3 mg/min/kg × 21 hr at 6 months 
vs. 20.3 ± 1.7 mg/min/kg × 21 hr at 12 months). Although all 
the monkeys initially gained weight on the high-fructose diet, 
the monkeys that subsequently developed diabetes lost weight 
aft er they became hyperglycemic and glycosuric, and had no net 
overall change of body weight (15.8 ± 0.3 kg at baseline vs. 15.6 
± 0.5 kg at 12 months). 
 Fasting glucose and insulin concentrations, glucose tolerance, 
and insulin sensitivity. 
 In the majority of the monkeys studied, exposure to the high-
fructose diet did not result in overt diabetes and fasting glucose 
concentrations did not change (72 ± 2 mg/dL at baseline and 
12 months). However, fasting insulin concentrations increased 
dramatically (+121% at 6 months,  p  0.001; +95% at 12 months, 
 p  0.001), indicative of β-cell compensation for insulin resistance 
( Table 1 ). Furthermore, the area under the curve (AUC) for both 
glucose and insulin concentrations during intravenous glucose 
tolerance testing in the nondiabetic animals increased (AUC 
glucose: +18% at 6 months,  p  0.001; +20% at 12 months, 
p  0.001; AUC insulin: +76% at 6 months,  p  0.001; +70% 
at 12 months,  p  0.001) ( Figure 2A and B), and the calculated 
insulin sensitivity index (ISI) decreased (31% at 6 months, 
p  0.01; 41% at 12 months,  p  0.001). In addition, the 
calculated homeostasis model of insulin resistance (HOMA-
IR) values and ISI values were signifi cantly correlated at each 
time point ( r = 0.60 at baseline,  p  0.01;  r = 0.55 at 6 months, 
 p  0.05;  r = 0.68 at 12 months,  p  0.001) throughout the 
study. In the monkeys that developed diabetes, fasting glucose 
concentrations increased (79 ± 3 mg/dL at baseline vs. 171 ± 
7 mg/dL at 12 months), whereas the increases of fasting insulin 
concentrations were insufficient to prevent hyperglycemia, 
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suggesting inadequate β-cell 
compensation. The AUC for 
glucose levels during intravenous 
glucose tolerance testing also 
progressively increased from 
baseline during the study period, 
suggesting worsening glucose 
disposal ( Figure 2C ). As expected, 
the AUC for insulin concentrations 
in the diabetic animals dramatically 
decreased due to progressive β-cell 
insuffi  ciency ( Figure 2D ). 
 Fasting lipid and lipoprotein 
c o n c e n t r a t i o n s .  I n  t h e 
normoglycemic, insulin resistant 
monkeys, fasting triglyceride (TG) 
concentrations increased (+61% at 
6 months,  p  0.001; +87% at 12 
months,  p  0.001) and fasting 
high-density lipoprotein cholesterol 
(HDL-C) levels decreased (13% 
at 6 months,  p  0.01; 14% at 12 
months,  p  0.01) during the course 
of the study ( Table 2 ). Fasting total 
cholesterol (TC) concentrations 
did not change, nor did fasting 
low-density lipoprotein cholesterol 
(LDL-C) or oxidized LDL-C 
(oxLDL-C) levels. Furthermore, 
fasting apolipoprotein B (ApoB) 
concentrations did not change 
during the study period. However, 
fasting apolipoprotein A1 (ApoA1) 
levels decreased (9% at 6 months, 
 p  0.01; 5% at 12 months,  p  
0.05) and fasting apolipoprotein 
C3 (ApoC3) levels increased 
(+14% at 12 months,  p  0.01). 
In the monkeys that developed 
diabetes, fasting TC concentrations, 
LDL-C concentrations, oxLDL-C 
concentrations, TG concentrations, 
and ApoC3 concentrations all 
increased over the course of 
the study, while fasting HDL-C 
levels and ApoA1 concentrations 
decreased. 
 Adipocyte hormones. In the 
normoglycemic monkeys with 
metabolic syndrome, fasting 
plasma leptin concentrations 
increased over the course of 
the study (+40% at 6 months, 
p  0.001; +42% at 12 months, 
 p  0.001) in parallel with the 
increases of body weight and 
adiposity ( Table 3 ). Alternatively, 
both fasting total adiponectin 
levels (27% at 6 months,  p  
0.001; 28% at 12 months,  p  
0.001) and fasting high molecular 
 Figure 1. The effect of a high-fructose diet on (A) body weight, (B) fat mass, (C) energy intake, and (D) energy expenditure 
in rhesus monkeys with diet-induced metabolic syndrome. *p  0.05, **p  0.01, ***p  0.001 versus baseline by linear 
mixed model. Error bars show SEM. 
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weight (HMW) adiponectin levels (44% at 6 months,  p  0.001; 
47% at 12 months,  p  0.001) decreased in parallel with the 
monkeys’ decreased insulin sensitivity. Th e ratio of HMW to 
total adiponectin decreased as well (16% at 6 months,  p  
0.01; 20% at 12 months,  p  0.001). In the diabetic monkeys, 
fasting plasma leptin concentrations initially increased while the 
animals were gaining weight; however, once the animals became 
hyperglycemic, glucosuric, and began to lose weight, fasting 
plasma leptin levels declined. Furthermore, like in the insulin 
resistant monkeys, both fasting total and HMW adiponectin 
levels, as well as the HMW/total 
adiponectin ratio, decreased in the 
diabetic animals. 
 Fasting proinfl ammatory marker 
concentrations. In the nondiabetic 
monkeys with metabolic syndrome, 
plasma C-reactive protein (CRP) 
concentrations increased (+77% 
at 6 months,  p  0.001; +71% at 
12 months,  p  0.001) ( Table 4 ).
Although fasting monocyte 
chemotactic protein-1 (MCP-1) and 
plasminogen activator inhibitor-1 
(PAI-1) levels also increased, the 
results were only significant for 
MCP-1 (+36% at 6 months,  p  
0.001). In the diabetic monkeys, 
CRP and MCP-1 concentrations 
increased, whereas PAI-1 levels 
decreased. 
 Discussion 
 In this novel study, we demonstrate that fructose-sweetened 
beverages are well tolerated by rhesus monkeys and that 
within a 6- to 12-month period of time, consumption of a 
high-fructose diet in monkeys produces many of the features 
of metabolic syndrome in humans, including central obesity, 
insulin resistance, infl ammation, and dyslipidemia. In a subset 
of animals, the high-fructose diet also results in overt T2DM. 
Th us, this rhesus monkey model of diet-induced obesity, insulin 
resistance, and dyslipidemia is directly translatable to metabolic 
syndrome in humans. In addition, due to the rapidity with which 
Monkeys with metabolic syndrome Monkeys with diabetes
Measurement n Time Result % n Time Result %
Glucose (mg/dL) 25 Baseline 72 ± 2 4 Baseline 79 ± 3
6 months 73 ± 2 – 6 months 114 ± 13 +44%
12 months 72 ± 2 – 12 months 171 ± 7 +116%
Insulin (µU/mL) 25 Baseline 54 ± 8 4 Baseline 133 ± 58
6 months 148 ± 29 +121%c 6 months 252 ± 149 +89%
12 months 121 ± 26 +95%c 12 months 184 ± 117 +38%
AUC glucose 19 Baseline 9,339 ± 566 2 Baseline 12,890 ± 587
6 months 10,991 ± 573 +18%c 6 months 13,078 ± 1276 +2%
12 months 11,172 ± 397 +20%c 12 months 13,352 ± 2,555 +4%
AUC insulin 19 Baseline 16,239 ± 3,241 2 Baseline 7,337 ± 1080
6 months 33,953 ± 10,322 +76%c 6 months 1,690 ± 1,220 −77%
12 months 28,053 ± 6,840 +70%c 12 months 673 ± 322 −91%
Insulin sensitivity 19 Baseline 0.69 ± 0.11
Index 6 months 0.48 ± 0.08 −31%b
12 months 0.41 ± 0.09 −41%c
Mean ± SEM.
ap  0.05; bp  0.01; cp  0.001.
Abbreviations: AUC, area under the curve.
 Table 1.  The effects of a high-fructose diet on fasting glucose and insulin concentrations, glucose tolerance, and insulin sensitivity during an intravenous glucose tolerance 
test in rhesus monkeys. 
 Figure 1.  Continued. 
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the metabolic changes occur, this model presents a practical 
system with which to study the pathogenesis, prevention, and 
treatment of metabolic syndrome and T2DM and can serve 
as a means to evaluate these processes in long-term studies 
with assured compliance in a manner that cannot practically 
be performed in humans. 
 Importantly, this diet-induced nonhuman primate model will 
be useful in several active areas of investigation directly applicable 
 Figure 2.  The glucose ( A ) and insulin ( B ) responses during intravenous glucose tolerance testing in rhesus monkeys with diet-induced metabolic syndrome, and the glucose 
( C ) and insulin ( D ) responses during intravenous glucose tolerance testing in rhesus monkeys with diet-induced diabetes. Error bars show SEM. 
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 Figure 2.  Continued. 
Monkeys with metabolic syndrome Monkeys with diabetes
Measurement n Time Result % n Time Result %
Cholesterol (mg/dL) 25 Baseline 163 ± 6 4 Baseline 153 ± 11
6 months 154 ± 7 −6% 6 months 154 ± 8 –
12 months 159 ± 8 −4% 12 months 232 ± 48 +52%
LDL-C (mg/dL) 19 Baseline 74 ± 4 2 Baseline 70 ± 4
6 months 66 ± 5 −14% 6 months 70 ± 6 –
12 months 78 ± 7 +3% 12 months 101 ± 2 +44%
OxLDL-C (U/l) 25 Baseline 24.1 ± 1.8 4 Baseline 25.1 ± 1.4
6 months 23.5 ± 1.7 −2% 6 months 31.6 ± 3.0 +26%
12 months 26.3 ± 2.4 +6% 12 months 54.4 ± 9.0 +117%
HDL-C (mg/dL) 25 Baseline 72 ± 3 4 Baseline 65 ± 12
6 months 62 ± 4 −13%b 6 months 45 ± 7 −31%
12 months 62 ± 4 −14%b 12 months 39 ± 5 −40%
TG (mg/dL) 25 Baseline 79 ± 9 4 Baseline 94 ± 23
6 months 134 ± 18 +61%c 6 months 322 ± 82 +243%
12 months 155 ± 19 +87%c 12 months 680 ± 239 +623%
Apo A1 (mg/dL) 19 Baseline 134 ± 3 2 Baseline 111 ± 3
6 months 122 ± 4 −9%b 6 months 94 ± 4 −15%
12 months 126 ± 3 −5%a 12 months 73 ± 13 −34%
Apo B (mg/dL) 19 Baseline 46.8 ± 2.6 2 Baseline 48.2 ± 1.8
6 months 43.4 ± 2.9 −7% 6 months 47.0 ± 6.0 −2%
12 months 47.7 ± 3.4 +2% 12 months 64.0 ± 1.5 +33%
Apo C3 (mg/dL) 23 Baseline 4.74 ± 0.19 4 Baseline 5.03 ± 0.41
6 months 5.17 ± 0.37 +4% 6 months 7.40 ± 0.23 +47%
12 months 5.46 ± 0.28 +14%b 12 months 10.15 ± 1.81 +102%
Mean ± SEM.
ap  0.05; bp  0.01; cp  0.001.
Abbreviations: LDL-C, low-density lipoprotein cholesterol; oxLDL-C, oxidized low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; 
Apo, apolipoprotein.
 Table 2.  The effects of a high-fructose diet on fasting lipid and lipoprotein concentrations in rhesus monkeys. 
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to humans. First, since the genome of the rhesus macaque is 
known, 21 , 24 this model permits comparative studies with humans 
and the direct linkage of genotype with phenotype (insulin defi cient 
and hyperglycemic vs. insulin suffi  cient and normoglycemic), 
and thus can provide important insight into the genes involved 
in the susceptibility for β-cell failure and the development of 
T2DM versus metabolic syndrome. Given the serious clinical 
implications of diabetes and the increased risk for both macro- 
and microvascular complications in diabetic subjects, a further 
understanding of genetic factors contributing to diabetes is needed. 
Th is model off ers a valuable opportunity to perform these types of 
genotype-phenotype studies in a controlled fashion, and can lead 
to a better understanding of how genetic variability infl uences the 
development of insulin resistance and its treatment. 
 Second, the model permits the time- and cost-eff ective study 
of new treatment strategies for insulin resistance-associated 
metabolic disorders. Due to the high prevalence of insulin 
resistance and insulin resistance-related conditions, and the 
estimate that diabetes will aff ect more than 324 million people 
worldwide by the year 2025, 42 many new and investigational 
agents are currently being generated to improve insulin sensitivity 
and prevent the onset of diabetes. 43 Th ese compounds include 
insulin receptor tyrosine kinase and insulin mimetics, protein 
tyrosine phosphatase-1B (PTP-1B) inhibitors, glycogen synthase 
kinase-3 (GSK3β) inhibitors, and inhibitors of Inhibitor KappaB 
Kinase (IKKβ). 43 Although many of these agents have been studied 
 in vitro and in cultured mammalian cells, only a few have been 
studied in animals; and, those agents that have been evaluated in 
animals have mostly been in rodent models. 
 As proof of principle, our laboratory recently demonstrated 
the utility of this rhesus monkey model of diet-induced metabolic 
syndrome in the evaluation of new pharmaceutical agents by 
investigating the eff ects of one of these novel agents, an antisense 
oligonucleotide (ASO) directed against PTP-1B (ISIS 113715), 
Monkeys with metabolic syndrome Monkeys with diabetes
Measurement n Time Result % n Time Result %
Total adiponectin (µg/mL) 23 Baseline 7.12 ± 0.95 4 Baseline 5.44 ± 0.97
6 months 5.06 ± 0.74 −27%c 6 months 4.47 ± 0.02 −18%
12 months 5.05 ± 0.64 −28%c 12 months 3.17 ± 1.00 −42%
HMW adiponectin (µg/mL) 25 Baseline 2.25 ± 0.34 4 Baseline 1.63 ± 0.51
6 months 1.31 ± 0.22 −44%c 6 months 0.88 ± 0.35 −46%
12 months 1.23 ± 0.19 −47%c 12 months 0.96 ± 0.38 −41%
HMW/Total adiponectin 25 Baseline 0.281 ± 0.016 4 Baseline 0.270 ± 0.060
6 months 0.237 ± 0.017 −16%b 6 months 0.320 ± 0.036 +18%
12 months 0.224 ± 0.015 −20%c 12 months 0.252 ± 0.058 −7%
Leptin (ng/mL) 25 Baseline 8.96 ± 0.89 4 Baseline 9.75 ± 1.53
6 months 12.53 ± 1.05 +40%c 6 months 11.74 ± 2.42 +20%
12 months 12.77 ± 0.86 +42%c 12 months 9.10 ± 2.32 −7%
Mean ± SEM.
ap  0.05; bp  0.01; cp  0.001.
Abbreviations: HMW, high molecular weight.
 Table 3.  The effects of a high-fructose diet on adipocyte hormones in rhesus monkeys. 
Monkeys with metabolic syndrome Monkeys with diabetes
Measurement n Time Result % n Time Result %
CRP (mg/L) 19 Baseline 1.63 ± 0.26 2 Baseline 1.49 ± 0.21
6 months 2.60 ± 0.26 +77%c 6 months 2.21 ± 0.71 +48%
12 months 2.59 ± 0.27 +71%c 12 months 1.98 ± 0.28 +33%
MCP-1 (pg/mL) 23 Baseline 232 ± 20 4 Baseline 340 ± 141
6 months 314 ± 27 +36%c 6 months 450 ± 168 +32%
12 months 289 ± 33 +14% 12 months 451 ± 172 +33%
PAI-1 (ng/mL) 19 Baseline 2.56 ± 0.55 2 Baseline 2.20 ± 0.36
6 months 3.60 ± 0.62 +45% 6 months 1.38 ± 1.01 −37%
12 months 3.36 ± 0.78 +17% 12 months 1.84 ± 1.28 −16%
Mean ± SEM.
ap  0.05; b  0.01; cp  0.001.
Abbreviations: CRP, C-reactive protein; MCP-1, monocyte chemotactic protein-1; PAI-1, plasminogen activator inhibitor-1.
 Table 4.  The effects of a high-fructose diet on proinfl ammatory markers in rhesus monkeys. 
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in these animals. 37 Specifi cally, we demonstrated that treatment 
of obese, nondiabetic, insulin resistant rhesus monkeys with 20 
mg/kg ISIS 113715 for 4 weeks reduced fasting plasma insulin 
concentrations by approximately 50%, reduced insulin responses 
during an intravenous glucose tolerance test by approximately 
25%, and increased total and HMW adiponectin concentrations 
by approximately 70–100%. Th is therapeutic approach targeting 
PTP-1B is currently in Phase 2 clinical trials in humans. Studies 
such as these thus reinforce the importance of establishing and 
having access to a well-characterized nonhuman primate model 
of metabolic syndrome, and demonstrate the novel information 
that can be gained by producing insulin resistant monkeys with 
metabolic syndrome such that new approaches developed to 
improve insulin sensitivity and prevent/treat obesity, dyslipidemia, 
and T2DM in humans can be effi  ciently and eff ectively evaluated 
in targeted preclinical studies. 
 Th e model has some potential limitations. Th e fi rst is the 
amount of fructose (~30% of energy) provided to the animals. 
However, recent data suggest that approximately 15% of the US 
population consumes ≥25% of energy from added sugars. 13 Two 
recent reviews have suggested that long-term sugar intakes as 
high as 25–50% of energy have no adverse eff ects with respect 
to components of the metabolic syndrome 44 and that fructose 
consumption up to 140 grams per day does not result in 
biologically relevant increases of fasting or postprandial TGs in 
healthy, normal weight humans. 45 However, these conclusions 
appear to be incorrect based on evidence from a number of 
studies and other reviews. 19 , 46 , 47 Another potential limitation is 
the lack of a “control” group not consuming fructose. However, 
we have previously conducted studies in humans designed to 
compare the metabolic eff ects of consuming fructose- versus 
glucose-sweetened beverages for 10 weeks. 19 Rather, the objective 
of this study was to create a nonhuman primate model of diet-
induced insulin resistance and dyslipidemia (and not to compare 
the metabolic eff ects of fructose vs. glucose in the animals). 
Furthermore, although rhesus monkeys can spontaneously 
develop features of the metabolic syndrome, studies suggest 
heterogeneity in the rate of progression and timing of expression. 48 
In our study, all animals developed features of the metabolic 
syndrome, usually within 6 months. Although it is possible that 
some of the animals may have developed metabolic syndrome 
spontaneously over time on a standard diet, the ingestion of 
a high-fructose diet consistently and quickly resulted in the 
development of metabolic syndrome components. Finally, only 
males were used in the study because the CNPRC reserves female 
monkeys for breeding purposes. Th ere may be some diff erences 
between the metabolic responses to a high-fructose diet in male 
and female monkeys. However, based on our previous study in 
which we compared the long-term metabolic consequences of 
consuming sugar-sweetened beverages in men and women, 19 we 
would expect to also see reduced insulin sensitivity and altered 
lipid profi les in female monkeys. 
 Importantly, major advantages of using this novel rhesus 
monkey model of diet-induced metabolic disease include the 
ability to  (i) longitudinally perform repeated procedures (such as 
skeletal muscle, hepatic, and intraabdominal fat biopsies), and  (ii) 
directly study the central nervous system and the neuroendocrine 
regulation of metabolism and weight homeostasis in a manner that 
cannot be performed in humans. Furthermore, use of this model 
ensures long-term compliance with dietary and pharmaceutical 
interventions, minimizing the confounding variables that 
invariably exist in long-term human studies. 
 Conclusions 
 Given the current trends in sugar consumption and the increasing 
incidence and prevalence of metabolic disorders and diabetes 
in the United States and worldwide, the development of a novel 
nonhuman primate animal model of diet-induced metabolic 
syndrome and T2DM has important implications for translational 
research. We have successfully demonstrated that, like in humans, 
consumption of a high-fructose diet in rhesus monkeys produces 
many of components of the metabolic syndrome; the adverse 
metabolic changes also occur rapidly (within 6 to 12 months), 
making the model practical for both prevention and treatment 
studies. Moreover, a subset of monkeys on a high-fructose 
diet develop overt T2DM, permitting the ability to perform 
genotype-phenotype studies in a controlled fashion evaluating 
the genetic factors involved in β-cell failure. Th us, fructose-fed 
rhesus monkeys represent a useful and effi  cient model system in 
which to systematically investigate the pathogenesis, prevention, 
and treatment of obesity, insulin resistance, dyslipidemia, and 
T2DM, and the model has signifi cant translational potential to 
improve the understanding and treatment of metabolic disorders 
in humans. 
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